文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SPIRIT-PRO 扩展说明和阐述:临床试验方案中纳入患者报告结局的指南。

SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

机构信息

Centre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK

Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.

出版信息

BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105.


DOI:10.1136/bmjopen-2020-045105
PMID:34193486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8246371/
Abstract

Patient-reported outcomes (PROs) are used in clinical trials to provide valuable evidence on the impact of disease and treatment on patients' symptoms, function and quality of life. High-quality PRO data from trials can inform shared decision-making, regulatory and economic analyses and health policy. Recent evidence suggests the PRO content of past trial protocols was often incomplete or unclear, leading to research waste. To address this issue, international, consensus-based, PRO-specific guidelines were developed: the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension. The SPIRIT-PRO Extension is a 16-item checklist which aims to improve the content and quality of aspects of clinical trial protocols relating to PRO data collection to minimise research waste, and ultimately better inform patient-centred care. This SPIRIT-PRO explanation and elaboration (E&E) paper provides information to promote understanding and facilitate uptake of the recommended checklist items, including a comprehensive protocol template. For each SPIRIT-PRO item, we provide a detailed description, one or more examples from existing trial protocols and supporting empirical evidence of the item's importance. We recommend this paper and protocol template be used alongside the SPIRIT 2013 and SPIRIT-PRO Extension paper to optimise the transparent development and review of trial protocols with PROs.

摘要

患者报告结局(PROs)在临床试验中被用于提供有价值的证据,以说明疾病和治疗对患者症状、功能和生活质量的影响。高质量的临床试验 PRO 数据可以为共同决策、监管和经济分析以及卫生政策提供信息。最近的证据表明,过去试验方案中的 PRO 内容往往不完整或不明确,导致研究浪费。为了解决这个问题,制定了基于国际共识的、专门针对 PRO 的指南:标准议定书项目:干预试验建议(SPIRIT)-PRO 扩展。SPIRIT-PRO 扩展是一个包含 16 个项目的清单,旨在提高与 PRO 数据收集相关的临床试验方案的内容和质量,以最大限度地减少研究浪费,并最终更好地为以患者为中心的护理提供信息。本文详细介绍并阐述了(E&E)文件提供了促进理解和促进推荐清单项目采用的信息,包括一个全面的方案模板。对于每个 SPIRIT-PRO 项目,我们提供了详细的描述、一个或多个来自现有试验方案的示例以及该项目重要性的支持性实证证据。我们建议在使用 SPIRIT 2013 和 SPIRIT-PRO 扩展文件的同时使用本文和方案模板,以优化具有 PRO 的试验方案的透明制定和审查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/f695e90bce9e/bmjopen-2020-045105f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/62aa7b68b5a0/bmjopen-2020-045105f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/34bcd292914c/bmjopen-2020-045105f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/8001749ba002/bmjopen-2020-045105f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/940a0e515644/bmjopen-2020-045105f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/f695e90bce9e/bmjopen-2020-045105f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/62aa7b68b5a0/bmjopen-2020-045105f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/34bcd292914c/bmjopen-2020-045105f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/8001749ba002/bmjopen-2020-045105f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/940a0e515644/bmjopen-2020-045105f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b42/8246371/f695e90bce9e/bmjopen-2020-045105f05.jpg

相似文献

[1]
SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

BMJ Open. 2021-6-30

[2]
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

JAMA. 2018-2-6

[3]
Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension.

JAMA. 2022-12-20

[4]
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

BMJ. 2013-1-8

[5]
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.

EClinicalMedicine. 2025-1-10

[6]
'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension.

BMJ Open. 2021-6-30

[7]
Guidelines for reporting pediatric and child health clinical trial protocols and reports: study protocol for SPIRIT-Children and CONSORT-Children.

Trials. 2024-1-30

[8]
SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

BMJ. 2025-4-28

[9]
Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols.

PLoS One. 2014-10-15

[10]
SPIRIT 2025 statement: Updated guideline for protocols of randomised trials.

PLoS Med. 2025-4-28

引用本文的文献

[1]
A Short Primer on the Reporting of Patient-Reported Outcome Measures in Clinical Studies.

Foot Ankle Orthop. 2025-8-12

[2]
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review.

Pharmaceut Med. 2025-5-14

[3]
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.

BMJ. 2025-4-28

[4]
Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials.

J Natl Cancer Inst Monogr. 2025-3-1

[5]
Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations.

J Patient Rep Outcomes. 2024-12-18

[6]
Data collection methods for patient-reported outcome measures in cancer randomised controlled trials: a protocol for a rapid scoping review.

BMJ Open. 2024-9-10

[7]
The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making.

Drugs R D. 2024-6

[8]
Impact of withholding early parenteral nutrition on 2-year mortality and functional outcome in critically ill adults.

Intensive Care Med. 2024-10

[9]
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration.

BMJ. 2024-7-9

[10]
Dissecting Through the Literature: A Review of the Critical Appraisal Process.

Cureus. 2024-5-4

本文引用的文献

[1]
'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension.

BMJ Open. 2021-6-30

[2]
Systematic review of the use of translated patient-reported outcome measures in cancer trials.

Trials. 2021-4-26

[3]
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Lancet Oncol. 2020-3-20

[4]
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Lancet Oncol. 2020-2

[5]
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.

Crit Rev Oncol Hematol. 2020-1-18

[6]
Moving beyond project-specific patient and public involvement in research.

J R Soc Med. 2020-1

[7]
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.

Lung Cancer. 2020-1

[8]
The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.

Health Qual Life Outcomes. 2019-10-16

[9]
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.

Lancet Oncol. 2019-9-30

[10]
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.

Clin Genitourin Cancer. 2019-7-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索